Stock Analysis on Net
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

$24.99

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying user area

Try for free

Gilead Sciences Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Gilead Sciences Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Accounts payable
Accrued rebates
Compensation and employee benefits
Income taxes payable
Allowance for sales returns
Accrual for settlement related to bictegravir litigation
Other
Other current liabilities
Current portion of long-term debt and other obligations, net
Current liabilities
Long-term debt, net, excluding current portion
Long-term income taxes payable
Deferred tax liability
Other long-term obligations
Long-term liabilities
Total liabilities
Preferred stock, par value $0.001 per share; none outstanding
Common stock, par value $0.001 per share
Additional paid-in capital
Accumulated other comprehensive income (loss)
Retained earnings
Total Gilead stockholders’ equity
Noncontrolling interest
Total stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Gilead Sciences Inc. current liabilities as a percentage of total liabilities and stockholders’ equity increased from 2021 to 2022 and from 2022 to 2023.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Gilead Sciences Inc. long-term liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2021 to 2022 and from 2022 to 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Gilead Sciences Inc. total liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2021 to 2022 and from 2022 to 2023.
Total Gilead stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Gilead Sciences Inc. total Gilead stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from 2021 to 2022 and from 2022 to 2023.